NPPA fixes prices of 22 drug formulations

The national drug pricing regulator NPPA has fixed the retail and ceiling prices of 22 formulations used for treatment of various ailments including HIV, bacterial infections and cardiac conditions among others.

While National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 20 formulations, it has also capped the ceiling prices of two formulations, a notification on the regulator’s website said.

The prices have been fixed/revised under the Drug (Prices Control) Order, 2013, it added.

The regulator has fixed ceiling prices of Co-trimoxazole (Sulphamethoxazole(A) and Trimethoprim(B) tablets used for treating a variety of bacterial infections and oral rehydration salt (ORS).

It has also fixed the retail prices of drugs manufactured and marketed by various firms such as Omeprazole Domperidone capsule used for treatment of acidity and gastroesophageal reflux disease, Clotrimazole Beclomethasone cream used for treating variety of inflamed fungal skin infections.

The regulator has also fixed the retail price of Rosuvastatin Clopidogrel tablet used to lower cholesterol level and triglycerides and Tenofovir Disoproxil Fumarate Lamividine Efavirenz tablet used in treatment of HIV, among others.

The NPPA is mandated to fix/revise the prices of controlled bulk drugs and formulations and to enforce prices and availability of the medicines in the country.

It also monitors the prices of decontrolled drugs in order to keep them at reasonable levels.

The regulator implements and enforces the provisions of the Drugs (Prices Control) Order.

It is also entrusted with the task of recovering amounts overcharged by manufacturers for the controlled drugs from the consumers.

  • Related Posts

    Commissioner FDA reviews enforcement measures

    Srinagar: Commissioner, Food & Drugs Administration (FDA), Jammu & Kashmir, Khalid Jahangir on Thursday held an introductory meeting with senior officers and field functionaries of Drug and Food Wing of the…

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Karnataka High Court Ashwagandha ruling offers interim relief to supplement makers challenging the FSSAI advisory on Ashwagandha extracts. The Karnataka High Court has stayed an advisory issued by the Food…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Commissioner FDA reviews enforcement measures

    Commissioner FDA reviews enforcement measures

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices